Apoptosis and cell proliferation in medullary carcinoma of the breast: A comparative study between medullary and non-medullary carcinoma using the TUNEL method and immunohistochemistry

Journal of Surgical Oncology

Volumn 70, Issue 4, 1999, Pages 209-216

  Kajiwara, Masaaki ^a   Toyoshima, Satoshi ^b   Yao, Takashi ^a   Tanaka, Masao ^a   Tsuneyoshi, Masazumi ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KITAKYUSHU MUNICIPAL MEDICAL CENTER   (Japan)

Author keywords

Apoptosis; Bcl 2; Immunohistochemistry; Medullary carcinoma of the breast; p53; Proliferative activity; TUNEL method

Indexed keywords

KI 67 ANTIGEN; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; DNA DETERMINATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MEDULLARY CARCINOMA; MITOSIS RATE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, MEDULLARY; CELL DIVISION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; KI-67 ANTIGEN; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032895397     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9098(199904)70:4<209::AID-JSO2>3.0.CO;2-6     Document Type: Article

References (46)

1. Moore OS, Foote FW: The relatively favorable prognosis of medullary carcinoma of the breast. Cancer 1949;2:635-642.
2. Richardson WW: Medullary carcinoma of the breast: A distinctive tumour type with a relatively good prognosis following radical mastectomy. Br J Cancer 1956;10:415-423.
3. Bloom HJG, Richardson WW: Host resistance and survival in carcinoma of the breast: A study of 104 cases of medullary carcinoma in a series of 1,411 cases of breast cancer followed for 20 years. Br Med J 1970;3:181-188.
4. Ridolfi RL, Rosen PP, Port A, et al.: Medullary carcinoma of the breast: A clinicopathologic study with 10 year follow-up. Cancer 1977;40:1365-1385.
5. Rapin V, Contesso G, Mouriesse H, et al.: Medullary breast carcinoma: A reevaluation of 95 cases of breast cancer with inflammatory stroma. Cancer 1988;61:2503-2510.
6. Hamlin IME: Possible host resistance in carcinoma of the breast: A histologic study. Br J Cancer 1968;22:383-401.
7. Shimokawara I, Imamura M, Yamanaka N, et al.: Identification of lymphocyte subpopulations in human breast cancer tissue and its significance: An immunoperoxidase study with anti-human T-and B-cell sera. Cancer 1982;49:1456-1464.
8. Pedersen L, Schiodt T, Holck S, et al.: The prognostic importance of syncytial growth pattern in medullary carcinoma of the breast. APMIS 1990;98:921-926.
9. Black MM, Speer FD: Nuclear structure in cancer tissues. Surg Gynecol Obstet 1957;105:97-102.
10. Bloom HJG, Richardson WW: Histological grading and prognosis in breast cancer: A study of 1,409 cases of which 359 have been followed for 15 years. Br J Cancer 1957;11:359-377.
11. Cook DL, Weaver DL: Comparison of DNA content, S-phase fraction, and survival between medullary and ductal carcinoma of the breast. Am J Clin Pathol 1995;104:17-22.
12. Thompson CB: Apoptosis in the pathogenesis and treatment of disease. Science 1995;267:1456-1462.
13. Kerr JFR, Wyllie AH, Currie AR: Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972;26:239-257.
14. Wyllie AH: Cell death. In Bowen ID, Lockshin RA (eds): "Biology and Pathology." London: Chapman & Hall, 1981:9-34.
15. Umansky SR: The genetic program of cell death: Hypothesis and some applications: transformation, carcinogenesis, ageing. J Theor Biol 1982;97:591-602.
16. Brusch W, Kleine L, Tenniswood M: The biochemistry of cell death by apoptosis. Biochem Cell Biol 1990;68:1071-1074.
17. Ucker DS: Death by suicide: One way to go in mammalian cellular development? New Biol 1991;3:103-109.
18. Williams GT: Programmed cell death: Apoptosis and oncogenesis. Cell 1991;65:1097-1098.
19. Gavrieli Y, Sherman Y, Ben-Sasson SA: Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992;119:493-501.
20. Tsujitani S, Shirai H, Tatebe S, et al.: Apoptotic cell death and its relationship to carcinogenesis in colorectal carcinoma. Cancer 1996;77:1711-1716.
21. Lynch DAF, Clarke AMT, Jackson P, et al.: Comparison of labelling by bromodeoxyuridine, MIB-I, and proliferating cell nuclear antigen in gastric mucosal biopsy specimens. J Clin Pathol 1994;47:122-125.
22. Ohyama S, Yonemura Y, Miyazaki I: Proliferative activity and malignancy in human gastric cancers: Significance of the proliferation rate and its clinical application. Cancer 1992;69:314-321.
23. Bedi A, Pasricha PJ, Akhtar AJ, et al.: Inhibition of apoptosis during development of colorectal cancer. Cancer Res 1995;55: 1811-1816.
24. Kerr JFR, Winterford CM, Harmon BV: Apoptosis: Its significance in cancer and cancer therapy. Cancer 1994;73:2013-2036.
25. Reed JC: Bcl-2 and the regulation of programmed cell death. J Cell Biol 1994;124:1-6.
26. Arends MJ, Mcgregor AH, Wyllie AH: Apoptosis is inversely related to necrosis and determines net growth in tumors bearing constitutively expressed myc, ras, and HPV oncogenes. Am J Pathol 1994;144:1045-1057.
27. Cattoretti G, Becker MHG, Key G, et al.: Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 1992;168:357-363.
28. Gerdes J, Lemke H, Baisch H, et al.: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984;133:1710-1715.
29. Yonish-Rouach E, Resnitzky D, Lotem J, et al.: Wid-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 1991;352:345-347.
30. Hockenbery DM, Nunez G, Milliman C, et al.: Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990;348:334-336.
31. Hockenbery DM, Zutter M, Hickey W, et al.: BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA 1991;88:6961-6965.
32. Shi Y, Glynn JM, Guilbert LJ, et al.: Role for c-myc in activation-induced apoptotic cell death in T cell hybridomas. Science 1992; 257:212-214.
33. Lane DP: p53, guardian of the genome. Nature 1992;358:15-16.
34. Vogelstein B, Kinzler KW: p53 function and dysfunction. Cell 1992;70:523-526.
35. Merrit AJ, Polten CS, Kemp CJ, et al.: The role of p53 in spontaneous and radiation-induced apoptosis in the gastrointestinal tract of normal and p53-deficient mice. Cancer Res 1994;54:614-617.
36. Reed JC: Bcl-2 and the regulation of programmed cell death. J Cell Biol 1994; 124:1-6.
37. Pezzella F, Morrison H, Jones M, et al.: Immunohistochemical detection of p53 and bcl-2 proteins in non-Hodgkin's lymphoma. Histopathology 1993;22:39-44.
38. Haldar S, Negrini M, Monne M, et al.: Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res 1994;54:2095-2097.
39. Hurlimann J, Larrinaga B, Vala DLM: bcl-2 protein in invasive ductal breast carcinomas. Virchows Arch 1995;426:163-168.
40. Gorczyca W, Markiewski M, Kram A, et al.: Immunohistochemical analysis of bcl-2 and p53 expression in breast carcinomas: Their correlation with Ki-67 growth fraction. Virchows Arch 1995;426:229-233.
41. Ham HJ, Ho LI, Liu CA, et al.: Down regulation of bcl-2 by p53 in nasopharyngeal carcinoma and lack of detection of its specific t(14;18) chromosomal translocation in fixed tissues. Histopathology 1996;28:317-323.
42. Stewart BW: Mechanisms of apoptosis: Integration of genetic, biochemical, and cellular indicators. J Natl Cancer Inst 1994;86: 1286-1296.
43. Jensen V, Jensen ML, Kiær H, et al.: MIB-1 expression in breast carcinomas with medullary features: An immunohistochemical study including correlations with p53 and bcl-2. Virchows Arch 1997;431:125-130.
44. Rodriguez-Villanueva J, Mcdonnell TJ: Induction of apoptotic cell death in non-melanoma skin cancer by interferon-α. Int J Cancer 1995;61:110-114.
45. Liu DL, Yang MQ, Eberhardt J, et al.: Repeated immunotherapy using intratumoral injection with recombinant interleukin-2 and tumor-infiltrating lymphocytes inhibits growth of breast cancer and induces apoptosis of tumor cells. Cancer Lett 1996;103:131-136.
46. Whiteside TL, Chikamatsu K, Nagashima S, et al.: Antitumor effects of cytolytic T lymphocytes (CTL) and natural killer (NK) cells in head and neck cancer. Anticancer Res 1996;16:2357-2364.